News

FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.

In a meta-analysis of 46 RCTs, behavioral interventions modestly improved HbA1c in youth with T1D; family-focused approaches worked best.

A GBD analysis of 204 countries estimated measles cases in children under 5 rose from 11.1 million in 2019 to 15.6 million in 2023.

Missed the AAP's new pediatric UTI guideline? This easy-to-read FAQ covers the key changes in diagnosis, treatment, imaging, and prevention.

Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.

Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.

Black race was the strongest predictor of T2-high inflammation in 451 children with severe asthma adjusted for social and environmental factors.

Researchers discuss how testosterone changes during early puberty may influence depression and anxiety symptoms in girls and implications for pediatricians.

A Mott Poll of 2,027 parents found 81% say having a baby costs too much; 73% strongly back state paid leave around birth.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Learn when your baby is ready for solids, choose safe purees or finger foods, prevent choking, prioritize iron, and introduce allergens confidently.

Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.

Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.

Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.

Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.

Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.

The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.

Children with FASD given choline before age 6 had 9.1% higher nonverbal IQ and 11.3% better working memory vs placebo 5 years after treatment.

A deep learning model reading 1 nondilated fundus photo predicted 1-year progression to high myopia in children with AUCs of 0.91-0.96.

Todd Wolynn, MD, MMM, FAAP, explains how pediatricians can address misinformation through empathetic communication and community engagement.

SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.

Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.

A teen’s track collapse reveals CPVT, a hidden inherited arrhythmia; rapid CPR/AED response and family cascade screening prevent sudden cardiac arrest across generations.

Poison center reports of intentional school exposures rose 287% in elementary and 112% in middle school children from 2000 to 2024.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.